
Nanobiomaterials and Nanomedicines for Metabolic Disorders
- 1st Edition - December 1, 2025
- Imprint: Elsevier
- Editors: Subhash C. Mandal, Nilanjan Ghosh, Amit Kumar Halder
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 8 9 4 2 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 9 4 3 - 9
Nanobiomaterials and Nanomedicines for Metabolic Disorders explores the application of nanoparticles and nanotechnology for a range of metabolic pathways and disorders. Divide… Read more
Purchase options

- Utilizes an interdisciplinary approach, bridging the fields of materials science and biomedical science to improve translational efficiency
- Covers a range of nanoparticles and nanotechnologies for diagnosis and treatment of metabolic disorders, aiding readers to select the most suitable for their work
- Details various metabolic pathways and disorders, including glycogen and lysosomal storage, type 2 diabetes and obesity, and metabolic vascular disorders
1. Clinical use of inorganic and organic nanoparticles in metabolic syndromes
2. Application of nanomedicines in mitigating oxidative stress
3. Nanomedicines to enhance oral bioavailability for metabolic disorders
4. Nanotechnology for the therapeutic use of biologics to treat metabolic disorders
Section II: Nanotechnology in metabolic disorders: diagnosis and therapy
5. Application of quantum dots in metabolic disorders
6. Medical imaging using nanotechnology
7. Nanorobotics: applications in metabolic disorders
8. Nanomaterials for three-dimensional printing in management of metabolic disorders
Section III: Nanomedicines for lifestyle metabolic disorders
9. Nanomedicines to alleviate hepatic metabolic disorders
10. Role of nanomedicines in type 2 diabetes
11. Nanomedicines for precise therapy in hyperlipidaemia & obesity
Section IV: Nanomedicines for cellular metabolic disorders
12. Application of nanotechnology in lysosomal storage diseases
13. Nanotechnology to target autophagy-mediated metabolic disorders
14. Application of nanomedicines in glycogen storage diseases
Section V: Nanomedicines for metabolic cardiovascular diseases
15. Nanotechnology for metabolic vascular diseases
16. Nanomedicines for the management of atherosclerosis
- Edition: 1
- Published: December 1, 2025
- Imprint: Elsevier
- Language: English
SM
Subhash C. Mandal
NG
Nilanjan Ghosh
AH
Amit Kumar Halder
Dr. Amit Kumar Halder is an Associate Professor at the Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, West Bengal, India. He is also Joint Division-in-Charge in the Division of Pharmaceutical Chemistry at the same institute. He received his Ph.D. in Pharmacy from Jadavpur University, India, in 2016. He has five years of teaching experience and five years of postdoctoral experience. He worked as a postdoctoral researcher in University of Kwazulu-Natal, South Africa for one year and in University of Porto, Portugal, for four years. His specialization is computational chemistry, synthetic medicinal chemistry and cancer biology. He has published 58 articles in international journals and four book chapters.